# OnCo record imspire150 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imspire150/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imspire150", "NCT02908672" ;
  schema:name "IMspire150"@en ;
  schema:description "IMspire150 tested adding the immunotherapy drug atezolizumab to the two targeted pills used for BRAF-mutant melanoma; the triple combination kept the cancer from growing for longer as judged by the treating doctors, which earned it approval, but it did not help people live longer."@en ;
  schema:url <https://onco.cc/trials/imspire150/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02908672> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:people <https://onco.cc/people/ralf-gutzmer/> .